According to the Wisdom Financial APP, Cassava Sciences (SAVA.US) announced that it has completed the third interim safety review of simufilam in an important late-stage clinical trial for Alzheimer's patients.

It was learned that the Data and Safety Monitoring Board (DSMB) pre-review meeting recommended that Cassava Sciences' important Phase 3 clinical study continue as planned without any modifications.

Today's latest dynamic news was announced in October 2023 after the mid-term safety MRI data, indicating that the mid-term safety MRI data showed no relation between Cassava Sciences' simufilam and the amyloid-related imaging abnormalities observed during treatment.

Cassava Sciences is a biotechnology company based in Texas, USA, focusing on developing innovative drugs for treating Alzheimer's disease. Its main development project includes a drug called simufilam, which aims to improve the cognitive abilities of Alzheimer's patients by restoring the normal structure and function of brain proteins.

Cassava Sciences has attracted wide attention in the clinical trials of Alzheimer's disease treatment drugs. The company's recent major developments involve the progress of simufilam in Phase 3 clinical trials, attracting high interest from investment institutions and the medical community focused on biotechnology companies. The success of these trials could bring potential breakthroughs in the treatment of Alzheimer's disease.

Benefiting from this bullish news, the company's stock price rose over 2% in pre-market trading in the US stock market.